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BACKGROUND: There are limited data available to indicate whether tumor grade, myometrial invasion, International Federation of Gynecol-
oncological outcomes might be influenced by the uterine manipulator,
which is used at the time of hysterectomy for minimally invasive surgery in
patients with endometrial cancer. The current evidence derives from
retrospective studies with limited sample sizes. Without substantial evi-
dence to support its use, surgeons are required to make decisions about its
use based only on their personal choice and surgical experience.
OBJECTIVE: To evaluate the use of the uterine manipulator on onco-
logical outcomes after minimally invasive surgery, for apparent early-stage
endometrial cancer.
STUDY DESIGN: We performed a retrospective multicentric study to
assess the oncological safety of uterine manipulator use in patients with
apparent early-stage endometrial cancer, treated with minimally invasive
surgery. The type of manipulator, surgical staging, histology, lympho-
vascular space invasion, International Federation of Gynecology and Ob-
stetrics stage, adjuvant treatment, recurrence, and pattern of recurrence
were evaluated. The primary objective was to determine the relapse rate.
The secondary objective was to determine recurrence-free survival, overall
survival, and the pattern of recurrence.
RESULTS: A total of 2661 women from 15 centers were included;
1756 patients underwent hysterectomy with a uterine manipulator and
905 without it. Both groups were balanced with respect to histology,Cite this article as: Padilla-Iserte P, Lago V, Tauste C,
et al. Impact of uterine manipulator on oncological
outcome in endometrial cancer surgery. Am J Obstet
Gynecol 2020;XX:x.exex.ex.
0002-9378/$36.00
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https://doi.org/10.1016/j.ajog.2020.07.025ogy and Obstetrics stage, and adjuvant therapy. The rate of recurrence
was 11.69% in the uterine manipulator group and 7.4% in the no-
manipulator group (P<.001). The use of the uterine manipulator was
associated with a higher risk of recurrence (hazard ratio, 2.31; 95%
confidence interval, 1.27e4.20; P¼.006). The use of uterine manipu-
lator in uterus-confined endometrial cancer (International Federation of
Gynecology and Obstetrics [FIGO] IeII) was associated with lower
disease-free survival (hazard ratio, 1.74; 95% confidence interval,
0.57e0.97; P¼.027) and higher risk of death (hazard ratio, 1.74; 95%
confidence interval, 1.07e2.83; P¼.026). No differences were found
regarding the pattern of recurrence between both groups (chi-square
statistic, 1.74; P¼.63).
CONCLUSION: In this study, the use of a uterine manipulator was
associated with a worse oncological outcome in patients with uterus-
confined endometrial cancer (International Federation of Gynecology and
Obstetrics IeII) who underwent minimally invasive surgery. Prospective
trials are essential to confirm these results.
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manipulatorhe primary treatment for early-T stage endometrial cancer is sur-
gery, performing a total hysterectomy
and bilateral salpingo-oophorectomy
with surgical staging, if it is indicated.1
The National Comprehensive Cancer
Network and the European Society of
Gynaecological Oncology consensus
recommends minimally invasive ap-proaches (laparoscopic/robotic) in pa-
tients with a disease limited to the uterus,
according to evidence reported from
randomized prospective studies (Gyne-
cologic Oncology Group LAP2 trial).
2
This approach leads to lower operative
morbidity and a shorter hospital stay
than open surgery, without compro-
mising oncological outcomes.3
The uterine manipulator is a device
commonly used in minimally invasive
gynecologic hysterectomy for benign
disease. It is inserted vaginally through
the cervical canal into the endometrial
cavity. It facilitates the uterus mobiliza-
tion during the surgery, generating ten-
sion on the main supporting elements of
the uterus to improve surgical field
exposure and provide a landmark for the
colpotomy.4MONTH 2020 AmWith the introduction of minimally
invasive approaches in gynecologic
oncology treatments, this uterine device
has been utilized for endometrial and
cervical cancers, with controversy
regarding its influence on the spread of
tumor cells and the risk of recurrence.
Recently, the Laparoscopic Approach to
Cervical Cancer trial reported a worse
than expected oncological outcome af-
ter a laparoscopic/robotic approach in
early-stage cervical cancer.5 One of the
hypotheses generated was that the
uterine manipulator might influence
this worse prognosis.6 The retrospective
European Surgery in Cervical Cancer
Comparing Different Surgical Ap-
proaches in Stage IB1 Cervical Cancer
study found the use of a manipulator
was associated with a decrease inerican Journal of Obstetrics & Gynecology 1.e1
AJOG at a Glance
Why was this study conducted?
The uterine manipulator is a device commonly used in minimally invasive hys-
terectomy surgery for endometrial cancer. However, without substantial evidence
to support its use, surgeons are required to make decisions about its use based
only on their personal choice and surgical experience.
Key findings
This study demonstrated how the use of uterine manipulator in early-stage
endometrial cancer (International Federation of Gynecology and Obstetrics
[FIGO] IeII) for minimally invasive surgery was associated with a higher
recurrence rate, lower disease-free survival, and higher risk of death than the same
surgery without its use.
What does this add to what is known?
This large, multicenter, retrospective study suggests that the use of a uterine
manipulator is associated with worse oncological outcomes in patients with
uterus-confined endometrial cancer. The use of a uterine device in oncological
minimally invasive surgery should be reconsidered.
Original Research GYNECOLOGY ajog.orgdisease-free survival in cervical cancer
in the minimally invasive group.7
Therefore, there are reasonable doubts
about the uterine manipulator’s safety
in hysterectomy performed because of
cancer.
In endometrial cancer, the presence
of the uterine device in a cavity lined
with neoplastic tissues leads to a po-
tential tumor-manipulator interaction.
Multiple mechanisms are potentially
involved in this relationship but are
poorly understood; however, the
concept of uterus-confined disease is
important to evaluate these in-
teractions.8 Nonetheless, we have
limited evidence from retrospective
studies about the uterine manipulator
in endometrial cancer surgery, in
which no impact of the uterine ma-
nipulator’s use on oncological
outcome has been found.9e12 To date,
it remains a controversial conclusion
that the theoretical tumor manipula-
tion has no clear impact on the onco-
logical prognosis in endometrial
cancer.
In this retrospective multicenter
study, we hypothesized that the use of
the uterine manipulator might have an
impact on oncological outcomes after
minimally invasive surgery in patients
with apparent early-stage endometrial
cancer.1.e2 American Journal of Obstetrics & GynecologyMaterials and Methods
This is a multicenter retrospective study
endorsed by the Spanish Investigational
Network Gynecologic Oncology Group
(Spain-GOG) and conducted after
obtaining the Institutional Review Board
approval. All researchers involved in the
study agreed to treat the data confiden-
tially in accordance with the General
Data Protection Regulation.13
Study design
We retrospectively evaluated the influ-
ence of the uterine manipulator on the
oncological outcomes in a large cohort
of endometrial cancer patients coming
from multicenter Spanish participation.
Two cohorts of patients with apparent
early-stage endometrial cancer treated
with minimally invasive surgery were
evaluated, with and without uterine
manipulator use. The primary objective
was to determine the relapse rate. The
secondary objective was to determine
recurrence-free survival, overall survival,
and pattern of recurrence.
Cohort selection and study
variables
We included patients with the disease
apparently confined in the uterus at the
time of surgery, with histologic confir-
mation of endometrial cancer in which a
hysterectomy and bilateral salpingo-MONTH 2020oophorectomy were performed. Pa-
tients with surgical staging according to
the International Federation of Gyne-
cology and Obstetrics (FIGO) recom-
mendations were also included.14
Apparent early-stage disease was pre-
operatively defined as the disease being
confined to the uterus according to
myometrial imaging assessment (trans-
vaginal ultrasound and pelvic magnetic
resonance imaging) and/or intra-
operative assessment of the surgical
specimen by the pathologist. In type II
histology, to evaluate extrauterine
involvement, additional imaging pro-
cedures were performed (computed to-
mography [CT] or positron emission
tomographyeCT scanner).3 Patients
with suspected disease beyond the uterus
in preoperative assessment or confirmed
disease during surgical exploration were
excluded. Cases with no pathologic
confirmation of endometrial cancer in
the final surgical specimen (vanishing
endometrial carcinoma) or final histol-
ogy of atypical hyperplasia/endometrial
intraepithelial neoplasia were also
excluded.15 Therefore, only patients with
suspected endometrial cancer confined
in the uterus at the time of surgery were
included.
All surgeries were performed by
minimally invasive approach, performed
either by laparoscopic hysterectomy, ro-
botic hysterectomy, or laparoscopically
assisted vaginal hysterectomy. Open
surgery, conversion to laparotomy, or
only vaginal hysterectomy was excluded.
Patients unfit for standard surgery owing
to their medical condition were also
excluded (Figure 1).
The surgical variables collected were
the use of a uterine manipulator (the
type of uterine manipulator and sub-
type classification with or without in-
trauterine balloon), sealing of the
fallopian tubes, surgical staging pro-
cedure, surgical time, and hospital stay.
Final surgery histology data were gath-
ered as the tumor type and grade ac-
cording to the World Health
Organization classification, myometrial
invasion, presence of lymphovascular
space invasion (LVSI), and the number
of pelvic and paraaortic lymph nodes.16
Bokhman’s dualistic classification of
FIGURE 1
Study population
1Other reasons included lack of data on whether a uterine manipulator was used or not, type of
uterine device, final histologic diagnosis on nonendometrial cancer, and lack of data on relapse and/
or pattern of recurrence.
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tumors were classified using FIGO
staging.17,18 Finally, the data of adjuvant
treatment (vaginal brachytherapy,
external beam radiation (EBRT), and
chemotherapy scheme), time of follow-
up, time to relapse, and type and pattern
of recurrence were collected.
Statistical analysis
Data were summarized using the mean
(standard deviation) in the case of
numeric variables and absolute and
relative frequencies in the case of cate-
gorical variables. To assess the effect of
the uterine manipulator on disease-free
survival, a mixed-effects Cox regression
model was adjusted.19
The factors in our survival model were
adapted from 2 validated nomograms
predicting survival in endometrial can-
cer: type II histology, vaginal brachy-
therapy, EBRT, chemotherapy, FIGO
stage, and the interaction between the
manipulator used and FIGO stage, as
explicative variables.20,21 A random
intercept was included for each center to
control for the nonindependence of the
observations. Because FIGO did not
indicate a linear trend, the model was
segmented for these variables with a
breakpoint at FIGO III. In this model,
LVSI was not included owing to the high
number of missing values. Therefore, we
performed a sensitivity analysis by
imputing the missing values of LVSI and
readjusting the survival model. The
missing values of LVSI were imputed
using the nonparametric imputation
method provided in the missForest
package.22
Differences in the pattern of recur-
rence between both groups were also
assessed using multinomial logistic
regression. The effect of the uterine
manipulator use on overall survival was
also evaluated using a competing risks
model.23 In addition, a sensitivity anal-
ysis using propensity score matching,
based on the same covariates used to fit
the multivariable model, was performed.
Thus, the Rosenbaum method for
matched data was used to estimate the
degree of robustness of the observed
differences to changes in the odds of
differential assignment to themanipulator group owing to unobserved
confounders.24
For all estimates, 95% confidence in-
tervals (CIs) were calculated. All statis-
tical analyses were performed using R
(version 3.6.2) and the R packages clickR
(version 0.4.47), coxme (version 2.2-16),




The retrospective study was conducted
using the data collected from 15 national
centers with a mean recruitment period
of 8.33.6 years (range, 3e13). A total of
2661 women underwent primary sur-
gery for endometrial cancer by a mini-
mally invasive approach and met the
inclusion criteria: 1756 with a uterine
manipulator and 905 without a uterine
manipulator. Both groups were balanced
with respect to baseline characteristics
(Table 1).
Of the 1756 patients in whom a uter-
ine manipulator was used, in 909 pa-
tients (51.77%), an intrauterine inflatedMONTH 2020 Amballoon manipulator was used: VCare
(ConMed Corporation, Utica, NY) in
41.4% and Rumi-Koh (CooperSurgical
Inc, Trumbull, CT) in 10.36% of the
patients. In 847 patients, a no-balloon
manipulator was used: Cohen intra-
uterine cannula (Sklar Surgical In-
struments, West Chester, PA) in 17.2%,
Clermont-Ferrand (Karl Storz SE & Co
KG, Tuttlingen, Germany) in 26.94%,
and Valtchev uterine mobilizer (Conkin
Surgical Instruments Ltd, Vancouver,
Canada) in 4.1%.
There were relevant differences be-
tween the uterine manipulator and no-
uterine manipulator groups with
respect to surgical procedures: pelvic
and paraaortic lymphadenectomy
(P<.001). There were no differences
between the 2 groups with respect to the
final Bokhman’s classification types I
and II, tumor grade, myometrial inva-
sion, maximum tumor diameter, or the
number of lymph nodes harvested.
There was a higher rate of LVSI in the
uterine manipulator group (24.56% vs
11.76%; P<.001).erican Journal of Obstetrics & Gynecology 1.e3
TABLE 1








Age, y (mean [SD]) 64.71 (10.93) 65.34 (10.86)
BMI, kg/m2 (mean [SD]) 30.36 (6.17) 29.26 (5.95)
Balloon manipulator 909 (51.77) 0
Pelvic lymphadenectomy 1084 (61.73) 475 (52.49)
Paraaortic lymphadenectomy 574 (40.65) 223 (24.67)
Infracolic omentectomy 118 (6.72) 49 (5.43)
Surgical time, min (mean [SD]) 191.76 (78.43) 190.67 (82.99)
Hospitalization time, d (mean [SD]) 4.22 (4.42) 3.05 (3.50)
Bokhman’s classificationa
Type I 1345 (76.73) 692 (77.06)
Type II 408 (23.27) 206 (22.94)
Myometrial invasion
50% 1239 (70.68) 591 (65.38)
>50% 514 (29.32) 313 (34.62)
Maximum tumor diameter, mm (mean [SD]) 29.37 (18.85) 30.80 (22.40)
LVSI 379 (24.56) 102 (11.76)
Histologic data
Endometrioid G1 718 (40.96) 467 (52.00)
Endometrioid G2 619 (35.31) 220 (24.50)
Endometrioid G3 200 (11.41) 100 (11.14)
Serous 97 (5.53) 54 (6.01)
Clear cells 47 (2.68) 23 (2.56)
Carcinosarcoma 24 (1.37) 16 (1.78)
Pelvic lymph nodes removed (mean [SD]) 12.87 (6.37) 13.66 (6.94)
Paraaortic lymph nodes removed (mean [SD]) 8.63 (6.89) 10.13 (6.17)
Data are presented as number (percentage) unless indicated otherwise.
BMI, body mass index; LVSI, lymphovascular space invasion in surgical specimen; SD, standard deviation.
a Bokhman’s type dualistic model.
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summarized in Table 2. Most of the
tumors were confined to the uterus
(90.88% in the uterine manipulator
group and 91.09% in the no-
manipulator group). There were no
relevant differences between the 2
groups in lymph nodes metastasis
(5.18% vs 5.97%). Half of the patients
in both groups received adjuvant
radiotherapy, with combined EBRT
with vaginal brachytherapy as the most
commonly used modality. There were1.e4 American Journal of Obstetrics & Gynecologyno differences in the mean follow-up
period (45.67 vs 43.35 months).
Survival analysis
A total of 272 patients presented a
recurrence during the follow-up period,
205 patients with uterine manipulator
use (11.67%) and 67 patients without
uterine manipulator (7.4%) (P<.001).
Most of the recurrences in both groups
occurred as peritoneal carcinomatosis
(34.63% and 37.31%, respectively) or
visceral metastasis (35.12% and 34.32%,MONTH 2020respectively). Recurrences in the vaginal
vault were similar in both groups
(12.69% and 11.92%, respectively;
P¼.26). A total of 176 patients died
directly because of endometrial cancer:
137 patients in the uterine manipulator
group (7.8%) and 39 patients in the no-
uterine manipulator group (4.3%).
After adjusting for type II histology,
adjuvant administration of vaginal
brachytherapy, EBRT, chemotherapy,
and FIGO stage, the uterine manipulator
use was associated with a higher risk of
recurrence than the no-uterine manip-
ulator group (hazard ratio [HR], 2.31;
95% CI, 1.27e4.20; P¼.006) (Table 3).
The decrease in recurrence-free sur-
vival with uterine manipulator use was
only statistically significant in FIGO IeII
(HR for the interaction with FIGO IA to
II, 1.74; 95% CI, 0.57e0.97; P¼.027) but
not in FIGO III (HR for the interaction
with FIGO IIIA to IIIC2, 2.22; 95% CI,
0.85e5.83; P¼.1). No differences were
found regarding the pattern of recur-
rence between both groups according to
the multinomial regression model (chi-
square statistic, 1.74; P¼.63).
The differences in recurrence-free
survival based on the subtype of the
manipulator used (balloon vs no-
balloon device) were also assessed.
With this goal, a Cox regression model
was only adjusted to the group that used
a uterine manipulator. Results revealed
no statistically significant differences
between both groups (HR, 1.41 balloon
manipulator vs no-balloon manipulator
group; 95% CI, 0.71e2.78; P¼.33).
Regarding overall survival, after
adjustment for type II histology, adju-
vant administration of vaginal brachy-
therapy, EBRT, chemotherapy, and
FIGO stage, a statistically significant as-
sociation was found between the use of a
uterine manipulator and higher risk of
death in FIGO IeII (HR, 1.74; 95% CI,
1.07e2.83; P¼.026) but not in FIGO III
(HR, 1.02; 95% CI, 0.54e1.9; P¼.96)
(Figure 2).
Unfortunately, because of the high
number of missing values, the LVSI
could not be included in the statistical
model. For this reason, a sensitivity
analysis by imputing the missing values
of LVSI was performed, adjusting the
TABLE 2









FIGO IA 1139 (64.90) 554 (61.22)
FIGO IB 351 (20.00) 216 (23.87)
FIGO II 105 (5.98) 47 (5.19)
FIGO IIIA 44 (2.51) 26 (2.87)
FIGO IIIB 25 (1.42) 8 (0.88)
FIGO IIIC1 52 (2.96) 35 (3.87)
FIGO IIIC2 39 (2.22) 19 (2.10)
Adjuvant therapy
VBTa 388 (22.09) 214 (23.64)
EBRTb 34 (1.94) 11 (1.10)
VBTþEBRTc 507 (28.87) 219 (24.20)
Combined EBRTþchemotherapyd 126 (7.17) 73 (8.07)
Chemotherapy alonee 10 (0.57) 12 (1.33)
Relapse 205 (11.69) 67 (7.40)
Patterns of recurrence
Vaginal vault 26 (1.48) 8 (0.88)
Peritoneal carcinomatosis 71 (4.04) 25 (2.76)
Metastatic lymph nodes 32 (1.82) 6 (0.66)
Visceral metastases 72 (4.10) 23 (2.54)
Data are presented as number (percentage).
AUC, area under the curve; EBRT, external beam radiotherapy; FIGO, International Federation of Gynecology and Obstetrics;
VBT, vaginal brachytherapy.
a Most common schedule for exclusive vaginal cuff brachytherapy was 7 Gy for 3 fractions with a total dose of 21 Gy in vaginal
cuff; b Most common fractionation at 1.8e2 Gy per session with 5 sessions per wk, with a total dose of 45e50.4 Gy in the
pelvis, increasing to 50e55 Gy if there was microscopic pelvic lymph node involvement. Extended-field radiotherapy with 45
Gy, if microscopic paraaortic lymphatic node involvement was present; c Vaginal brachytherapy with 4.5e6 Gy after total
pelvic irradiation with 45Gy or VBT with 6 Gy if pelvis received 50.5 Gy; d There were several modalities. The most common
was 6 cycles of chemotherapy (carboplatin AUC 5þpaclitaxel 175 mg/m2 every 3 wk) and subsequent external beam
radiotherapy (45 Gy) with vaginal brachytherapy (20 Gy); e The most commonly used chemotherapy regimen was carboplatin
AUC 5þpaclitaxel 175 mg/m2 every 3 wk during 4e6 cycles.
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very similar between both models, so we
concluded that the noninclusion of LVSI
in our original model did not represent
bias to our results (Supplemental Table).
Results of the sensitivity analysis using
propensity score matching yielded a
criticalG value of 1.4, whichmeans that 1
patient in the matched pair may be up to
1.4 times more likely to be in the
manipulator group than in the no-
manipulator group because of different
values on unobserved covariates, and the
difference in relapse rates would still be
significant in favor of the no-manipulator
group (Supplemental Figures 1 and 2).
Discussion
Principal findings
This multicentric cohort study suggests
that patients who underwent a mini-
mally invasive surgery for early-stage
endometrial cancer in whom a uterine
manipulator was used presented a higher
rate of recurrence, lower recurrence-free
survival, and lower overall survival than
patients in whom a uterine manipulator
was not used. Our results contradict
previously published findings and call
into question the oncological safety of
the uterine manipulator use in endo-
metrial cancer.8e12 Uccella et al9 re-
ported the effect of a uterine
manipulator in patients with endome-
trial cancer by laparoscopic approach
(579 patients with uterine manipulator
vs 372 with no uterine manipulator).
They found no statistical differences in
recurrence rate (11.6% and 13.5%,
respectively) (odds ratio, 1.00; 95%
CI, 0.60e1.70; P¼.99), with a compara-
ble site of recurrence and no differences
among different types of manipulators.
These differences may be explained by
different factors. The low rate of recur-
rence in endometrial cancer is one factor.
The overall risk of recurrence is 13% for
all patients and 3% for patients at low
risk.25 When the magnitude of the dif-
ferences to test is low, large samples are
required to detect statistical significance;
therefore, conclusions from a small
sample size should be interpreted with
caution.26 In this scenario, previously
published studies included 534, 951,
110, 110, and 147 patients,respectively.8e12 The relapse rate in the
no-uterine manipulator group was
lower, but not statistically significant.
Nevertheless, the sample size of those
studies seems to limit their power to find
differences in the recurrence rate.
Results
The uterine manipulator is widely used
in benign gynecologic surgery because it
hypothetically decreases the complica-
tion rate and facilitates the surgery.
However, none of the data published to
date have indicated that a uterine deviceMONTH 2020 Amreduces surgical complications.8 In
endometrial cancer, the use of a uterine
device may be useful, because of high
rates of obesity in this population.25
Notwithstanding, current evidence sup-
ports that there is a real and safe possi-
bility to perform hysterectomy without
any uterine manipulator, even in adverse
situations.27,28
As is already known in other gyneco-
logic tumors (such as early-stage
epithelial ovarian cancer or morcella-
tion in unexpected uterine sarcoma),
when the confined disease is exposed toerican Journal of Obstetrics & Gynecology 1.e5
TABLE 3
Results of the mixed-effects Cox proportional hazards model for recurrence-free survival
Variables Estimate
Standard
error HR (95% CI) P value
Uterine manipulator 0.84 0.30 2.31 (1.27e4.20) .006
Type II histology 1.33 0.14 3.76 (2.83e4.99) <.001
Vaginal brachytherapy 0.28 0.16 0.76 (0.55e1.05) .092
EBRT 0.28 0.19 1.33 (0.92e1.92) .13
Chemotherapy 0.04 0.19 0.96 (0.67e1.40) .85
FIGO (IA to II) 0.49 0.12 1.64 (1.29e2.08) <.001
FIGO (IIIA to IIIC2) 0.77 0.43 0.46 (0.20e1.08) .074
FIGO (uterus-confined endometrial
cancer) and uterine manipulator
0.30 0.14 1.74 (0.57e0.97) .027
FIGO (no uterus-confined endometrial
cancer) and uterine manipulator
0.80 0.49 2.22 (0.85e5.83) .10
CI, confidence interval; EBRT, external beam radiation; FIGO, International Federation of Gynecology and Obstetrics; HR, hazard ratio.
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outcome worsens.29 Therefore, the
concept of organ-confined disease is an
essential idea to understand our results.
In early-stage endometrial cancer, the
myometrium acts as a containment
barrier, which may be iatrogenically
injured by the uterine manipulator.
Clinical implications
We observed a worse prognosis when the
uterine manipulator was used in patients
with uterus-confined diseases (FIGO
IeII), which was not present in patients
without uterus-confined diseases (FIGO
III), at the time of surgery. These results
support the concept that the uterine
manipulator might act in breaking the
uterus-confined disease and worsen the
oncological outcomes.
The different potential interferences,
summarized in Figure 3 and the Video,
may explain the alteration of the myo-
metrial barrier by the uterine device.
Therefore, 2 hypotheses are presented to
explain the relationship between the
uterine manipulator and endometrial
cancer.
First is the macroscopic injury hy-
pothesis. During the insertion of any
uterine manipulator (with or without
balloon) and its use (especially in the
atrophic uterus), themanipulator’s shank
may weaken the myometrium,1.e6 American Journal of Obstetrics & Gynecologyiatrogenically leading to uterine rupture
and opening of the tumor to the perito-
neal cavity and surgical field.30,31 The
uterine rupture is rarely reflected in sur-
gical reports, and it has not been
considered in previous analyses. Machida
et al32 reported a 0.4% to 1% perforation
rate with a balloon manipulator; thus,
other factors could be involved.
The second hypothesis is the micro-
scopic pathway of dissemination. The
uterine device generates a significant
increase in pressure inside the endome-
trial cavity, generating global distension
according to Pascal’s principle, which is
additionally increased by the maintained
push needed during uterine mobiliza-
tion and colpotomy.33 This increased
pressure might be involved in the
improved ability of tumor cells to exceed
the myometrial barrier, spreading
outside the uterus cavity by a passive
effect through the fallopian tubes and
lymphovascular space.34
Research implications
The pressure effect discussed has an
impact on the tumor microenvironment,
potentially helping to spread tumor cells
into the blood circulation intra-
operatively. This fact may also explain the
higher rate of distance recurrences related
to the use of uterine manipulators found
in this study. Tohme et al35 reported that aMONTH 2020higher trauma and manipulation of the
tumor enhanced the potential of meta-
static disease. Nevertheless, it remains
unclear why the increase in relapses is not
strongly associated with the lymphovas-
cular invasion.34 Some limitations in the
evaluation of LVSI in the surgical spec-
imen, such as tumor size, autolysis,
delayed formalin fixation, interobserver
variability, and pseudovascular artifact,
may lead to misinterpretation by pathol-
ogists and justify this lack of
association.36e38
Strengths and limitations
The main strength of our study is that the
sample size rose owing to multicenter
participation, which made an accurate
analysis possible because of the low rate of
recurrences in endometrial cancer. We
also included all different types of mini-
mally invasive approaches and long-term
survival data, which powered the results
of the study. To decrease the risk of bias,
we only recruited patients with histologic
confirmation in the final surgical spec-
imen to guarantee that, theoretically, all
uterine manipulators were in touch with
the tumor. We also performed the sub-
analysis in patients with the organ-
confined disease to demonstrate the ma-
nipulator’s effect.
Our trial has several limitations: above
all, the retrospective nature of the study
FIGURE 2
Survival analysis
Survival analysis in patients with endometrial cancer by minimally invasive surgery in the uterine manipulator group (green line) and no-manipulator
group (red line). The top of the figure represented the disease-free survival estimates using marginal effect plots of the mixed-effects Cox regres-
sion model. A, The disease-free survival estimates for FIGO IeII. B, The disease-free survival estimates for FIGO III. The bottom of the figure represented
the overall survival in use of uterine manipulator and nonuse of uterine manipulator using the Kaplan-Meier curves. C, The overall estimates for FIGO IeII.
D, The overall estimates for FIGO III.
CI, confidence interval; FIGO, International Federation of Gynecology and Obstetrics; HR, hazard ratio.
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ajog.org GYNECOLOGY Original Researchand the fact that there are centers that
contributed to only 1 branch of the
study. The surgical staging indication
depended on each center, which could
have affected the adjuvant therapy in-
dications. The pathologist assessment of
LVSI was not standardized. In the same
way, the coagulation of the fallopian
tubes was collected, but we could not use
this in the analysis because the quality of
the data was insufficient. The missing
LVSI data could influence our results,
and its relationship with the uterinedevice remains unclear. Finally, we were
only able to hypothesize about the rela-
tionship between tumors and uterine
manipulator, and more knowledge must
be sought.
Conclusion
This single study suggests that the use of
a uterine manipulator is associated with
worse oncological outcomes in patients
with uterus-confined endometrial cancer
(FIGO IeII) at the time of surgery; it also
presented a lower recurrence-freeMONTH 2020 Amsurvival and lower overall survival,
regardless of the type of manipulator
used, with no differences in the pattern of
recurrence. These results must be
confirmed in a prospective trial, with a
strict surgical reporting policy (including
reporting of tubal sealing, uterine perfo-
ration, and intraoperative complication)
and standard pathologist assessment. n
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SUPPLEMENTAL FIGURE 1
Kaplan-Meier curves for disease-free survival in use of uterine manipulator
and nonuse of uterine manipulator
CI, confidence interval; HR, hazard ratio.
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SUPPLEMENTAL FIGURE 2
Kaplan-Meier curves for overall survival in use of uterine manipulator and
nonuse of uterine manipulator
CI, confidence interval; HR, hazard ratio.
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SUPPLEMENTAL TABLE
Results of the mixed-effects Cox proportional hazards model for recurrence-free survival imputing the missing values
of LVSI
Variables Estimate Standard error HR (95% CI) P value
Uterine manipulator 0.80 0.30 2.25 (1.24e4.06) .007
Type II histology 1.28 0.14 3.61 (2.71e4.82) <.001
Vaginal brachytherapy 0.27 0.16 0.76 (0.55e1.04) .09
EBRT 0.25 0.19 1.29 (0.89e1.86) .13
Chemotherapy 0.06 0.19 0.94 (0.65e1.36) .73
LVSI 0.25 0.16 1.28 (0.94e1.75) .11
FIGO (IA to II) 0.48 0.12 1.62 (1.27e2.06) <.001
FIGO (IIIA to IIIC2) 0.76 0.43 0.43 (0.20e1.08) .076
FIGO (uterus-confined endometrial cancer) and uterine
manipulator
0.31 0.14 1.73 (0.56e0.95) .021
FIGO (no uterus-confined endometrial cancer) and
uterine manipulator
0.83 0.49 2.29 (0.87e6.03) .09
CI, confidence interval; EBRT, external beam radiation; FIGO, International Federation of Gynecology and Obstetrics; HR, hazard ratio; LVSI, lymphovascular space invasion.
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